Last reviewed · How we verify
Onychomycosis of toenails — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Jublia | EFINACONAZOLE | Bausch Health | Azole Antifungal [EPC] | 2014-01-01 | ||
| Sporanox | itraconazole | Sebela Ireland Ltd | Azole Antifungal [EPC] | C-X-C chemokine receptor type 1 | 1992-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bausch Health · 1 drug in Onychomycosis of toenails
- Sebela Ireland Ltd · 1 drug in Onychomycosis of toenails
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Onychomycosis of toenails:
- Onychomycosis of toenails treatment updates — RSS
- Onychomycosis of toenails treatment updates — Atom
- Onychomycosis of toenails treatment updates — JSON
Cite this brief
Drug Landscape (2026). Onychomycosis of toenails — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/onychomycosis-of-toenails. Accessed 2026-06-10.
Related
- Onychomycosis of toenails full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing